BioSpace News Archive

We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.

We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver innovative medicines for patients fighting serious diseases.

Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease.

Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Polaris Pharmaceuticals, is a biopharmaceutical development and manufacturing organization (CDMO) specializing in biologics derived from microbial systems.

Calico is an Alphabet-founded research and development company whose mission is to harness advanced technologies and model systems to increase our understanding of the biology that controls human aging.

Alkahest, a subsidiary of Grifols, is developing therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline -- key medical challenges of our generation.

Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies.

We’re celebrating 175 years of daring scientific innovation—and we’re not done yet. Every day, we’re channeling our passion and resources into delivering innovative therapies that change the face of healthcare. Let’s outdo yesterday.